Ambu A/S (AMBUb)

199.6
+9.3(+4.89%)
  • Volume:
    1,564,474
  • Bid/Ask:
    0.0/0.0
  • Day's Range:
    185.3 - 200.0
  • Type:Equity
  • Market:Denmark
  • ISIN:DK0060946788
  • S/N:223388932

AMBUb Overview

Prev. Close
190.3
Day's Range
185.3-200
Revenue
4.01B
Open
186
52 wk Range
157.4-358.7
EPS
0.98
Volume
1,564,474
Market Cap
50.65B
Dividend (Yield)
0.29
(0.15%)
Average Vol. (3m)
916,944
P/E Ratio
204.49
Beta
1.05
1-Year Change
1.04%
Shares Outstanding
253,732,461
Next Earnings Date
Feb 08, 2022
What is your sentiment on Ambu A/S?
or
Market is currently closed. Voting is open during market hours.

Ambu A/S Company Profile

Employees
4584
Market
Denmark

Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. It provides healthcare solutions in the fields of visualization, anesthesia, and patient monitoring and diagnostics. The company offers endoscopy products, such as bronchoscopes and monitors; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products. It also provides cardiology products consisting of ECG electrodes; and airway management and anaesthesia products, such as bronchoscopes, video laryngoscopes, double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers extrication collars, head immobilizers, CPR breathing barriers, and training manikins. Ambu A/S was founded in 1937 and is headquartered in Ballerup, Denmark.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyBuyNeutral
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong BuySell
  • Ambu (AMBU B) initiated with a Buy at Berenberg, Berenberg analyst Michael Healy initiated coverage of Ambu with a Buy rating and DKK 291 price target. Ambu is a leader in the "nascent" single-use endoscopy market, one of the fastest-growing segments in medical technology.
    0
    • Sack them all. Big talking American with their grand ideas of Sales at all cost.. . . Down here in Australia, every single American CEO they have tried in the past 20 years have run their companies to the ground and smashed the culture.. . . A great shame I have a very large position in this otherwise great company
      1
      • Feels like the Board of Directors do not like us shareholders. Time to spill the Board. Literally billions in value has been destroyed.
        0
        • They should not have cut Lars.
          0
        • René Rasmussen  Yep, gargantuan mistake. If you read the story of the Chairman, you will see he was fired as CEO from ALK in 2016. Was this revenge because he feels he was treated poorly? Either way I will post on their Facebook soon as I did here. It has cost me a lot of money.
          0
      • Remember when Lundbeck lost their CEO two years ago.. Same reaction and then soon forgotten.
        1
        • Ucchhh what fall today, and I just buy up in the fall. Hope it Will repair next week.
          0
          • Ambu is still a strong case. But it will take some month to stabelice.
            0
          • The leadership of ambu handles it without care.
            0
        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.